title: Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β2-agonists in Patients with Moderate to Severe Asthma: A Randomized, Controlled Study.
abstract: To evaluate and contrast the therapeutic effect and safety of fluticasone aerosol combined with theophylline tablets in patients with moderate to severe asthma, compared with salmeterol/fluticasone propionate aerosol.
  
  
  
  After a screening period, patients meeting the inclusion criteria were randomly assigned to the experiment group (fluticasone aerosol combined with theophylline tablets) or the control group (salmeterol/fluticasone aerosol combined with placebo tablets) for 12 weeks of treatment. The main outcome measurements were forced expiratory volume in 1 second and fractional concentration of exhaled nitric oxide value, whereas the secondary measures were forced vital capacity, peak expiratory flow value, and Asthma Control Test/Asthma Quality of Life Questionnaire score.
  
  
  
  Forty-four cases completed the course, with 23 cases in the experiment group and 21 cases in the control group. The forced expiratory volume in 1 second values of both groups were significantly improved from before (P < 0.05). The fractional concentration of exhaled nitric oxide values of both groups were significantly decreased from before (P < 0.05). The secondary outcome measurements after treatment achieved obvious improvement from baseline (P < 0.05) in both. There was no significant difference between the 2 groups in all measurements. In addition, the blood biochemistry results, ECG results, and vital signs of both groups had no significant abnormality.
  
  
  
  There was no significant difference in therapeutic effect and safety between the 2 groups in treating patients with moderate to severe persistent asthma, which suggests that fluticasone aerosol combined with theophylline tablets is worth considering for use in primary hospitals or for low-income populations.
authors.affiliation: The Institute Respiratory Disease, The First Hospital of China Medical University, Shenyang, Liaoning, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Respiratory Medicine, General Hospital of Shenyang Military Region, Shenyang, Liaoning, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Chen
authors.affiliation: The Institute Respiratory Disease, The First Hospital of China Medical University, Shenyang, Liaoning, China.
authors.forename: Anna
authors.initials: A
authors.lastname: Dai
authors.affiliation: The Institute Respiratory Disease, The First Hospital of China Medical University, Shenyang, Liaoning, China.
authors.forename: Shengyun
authors.initials: S
authors.lastname: Shang
authors.affiliation: The Institute Respiratory Disease, The First Hospital of China Medical University, Shenyang, Liaoning, China. Electronic address: konglingf@sina.com.
authors.forename: Lingfei
authors.initials: L
authors.lastname: Kong
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D058666:Adrenergic beta-2 Receptor Agonists / Q000627:therapeutic use*; D000328:Adult; D000336:Aerosols; D000368:Aged; D000420:Albuterol / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D000068298:Fluticasone / Q000627:therapeutic use*; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D013806:Theophylline / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D058666:Adrenergic beta-2 Receptor Agonists; D000336:Aerosols; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; D013806:Theophylline; D000068298:Fluticasone; D000420:Albuterol
keywords: fluticasone aerosol; moderate to severe persistent asthma; salmeterol/fluticasone propionate aerosol; theophylline tablets; treatment